SCHEMBL7073376

SCHEMBL7073376

COC(=O)CC(CS(=O)(=O)c1ccc(O)cc1)c1ccccc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.46
KMT2A Q03164 1/20 0.43
KCNA5 P22460 3/20 0.42
HSD11B1 P28845 1/20 0.41
MMP13 P45452 2/20 0.40
MMP2 P08253 2/20 0.40
MMP3 P08254 2/20 0.40
PDE4A P27815 2/20 0.40
PDE4B Q07343 2/20 0.40
PDE4C Q08493 2/20 0.40
PDE4D Q08499 2/20 0.40
CA12 O43570 1/20 0.40
CA7 P43166 1/20 0.40
CA9 Q16790 1/20 0.40
CA14 Q9ULX7 1/20 0.40
ESRRB O95718 1/20 0.39
F2 P00734 1/20 0.38
F10 P00742 1/20 0.38
PRSS1 P07477 1/20 0.38
MMP1 P03956 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7079124 0.88 ALDH1A1 (0.45) ALDH1A1KMT2AKCNA5HSD11B1MMP13
SCHEMBL7079059 0.88 ALDH1A1 (0.45) ALDH1A1KMT2AKCNA5HSD11B1MMP13
SCHEMBL7077837 0.85 ALDH1A1 (0.45) ALDH1A1KMT2AKCNA5MMP13MMP2
SCHEMBL7073753 0.85 GABBR2 (0.50) ALDH1A1KMT2AHSD11B1MMP2
SCHEMBL7073761 0.84 KMT2A (0.40) ALDH1A1KMT2A
SCHEMBL7078814 0.83 MMP13 (0.48) ALDH1A1MMP13MMP2MMP3PDE4A
SCHEMBL7075400 0.83 F2 (0.45) ALDH1A1KCNA5MMP13MMP2CA12
SCHEMBL7079922 0.83 MMP2 (0.43) ALDH1A1KCNA5HSD11B1MMP13MMP2
SCHEMBL7073767 0.82 MMP13 (0.49) ALDH1A1KMT2AKCNA5MMP13MMP2
SCHEMBL7078057 0.81 HSD11B1 (0.48) ALDH1A1KMT2AHSD11B1CA12CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2003059872-A1 AVB3 AND AVB5 INTEGRIN ANTAGONISTS AND METHODS OF TREATING DISEASES OR CONDITIONS ASSOCIATED WITH AVB3 AND AVB5 INTEGRINS BAYER PHARMACEUTICALS CORPORATION (US) 2003-07-24 WO disclosed
WO-2003059872-A1 AVB3 AND AVB5 INTEGRIN ANTAGONISTS AND METHODS OF TREATING DISEASES OR CONDITIONS ASSOCIATED WITH AVB3 AND AVB5 INTEGRINS BAYER PHARMACEUTICALS CORPORATION (US) 2003-07-24 WO disclosed